Doyle Mittie 4

What Happened

• Doyle Mittie, Chief Medical Officer of Avalo Therapeutics (AVTX), was granted a derivative award of 105,000 shares on February 26, 2026. The filing reports an acquisition price of $0.00 (derivative). Footnotes identify the grant as a stock option that vests 25% on Feb 26, 2027, with the remainder vesting in equal monthly installments over the following three years.
• This was a compensation grant (award), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-02-26; Filing date (Form 4): 2026-03-02 (timely within the 2 business‑day SEC window).
• Reported price: $0.00 (derivative award).
• Shares in transaction: 105,000 shares awarded.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote (F1): Option vests 25% on Feb 26, 2027; remaining vests monthly over the next 3 years, conditioned on continued service.
• No indication of sale, exercise, tax withholding, or a 10b5-1 plan in this filing.

Context

• This is a standard equity compensation grant to an executive. It represents future compensation subject to vesting and continued employment, not an immediate market purchase or sale. Because it’s a derivative (stock option) grant, there is no immediate cash exchanged or shares sold — eventual value will depend on future stock price and exercise terms.